United Therapeutics Corporation (Nasdaq: UTHR) has reported its financial results for the first quarter of 2025, showcasing a 17% increase in total revenues, which reached $794.4 million compared to $677.7 million in the first quarter of 2024. The company's net income rose by 5% to $322.2 million, up from $306.6 million in the previous year. Earnings per share also saw an increase, with net income per basic share at $7.18, a 10% rise from $6.52, and net income per diluted share at $6.63, a 7% increase from $6.17. The growth in revenues was primarily driven by an increase in sales of Tyvaso products, with total Tyvaso sales reaching $466.3 million, up from $372.5 million the previous year. This increase was fueled by higher sales of Tyvaso DPI, which contributed $302.5 million in sales, compared to $227.5 million in the first quarter of 2024. The company continues to focus on its growth strategy, including progressing with the readout of TETON 2 in idiopathic pulmonary fibrosis and the planned commencement of the UKidney first in human clinical study. Additionally, United Therapeutics is advancing its efforts to create an unlimited supply of transplantable organ alternatives, with anticipated filings of investigational new drug applications for its UHeart and UThymoKidney products.